Evidence map›Paper›PMID 41152341›Full record

ArticleScientific reports2025

Ovariectomy attenuates phenotypes related to Alzheimer's disease in a preclinical mouse model and in C57BL/6 J mice.

Kazuki Fujii, Yumie Koshidaka, Yuko Yanagibashi, Mayumi Adachi, Mina Matsuo, Kimihiro Kimura, Takashi Saito, Takaomi C Saido, Keizo Takao

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kazuki FujiiDepartment of Behavioral Physiology, Faculty of Medicine, University of Toyama, 2630 Sugitan, Toyama, 930-0194, Japan.
Yumie KoshidakaLife Science Research Center, University of Toyama, Toyama, Japan.
Yuko YanagibashiLife Science Research Center, University of Toyama, Toyama, Japan.
Mayumi AdachiLife Science Research Center, University of Toyama, Toyama, Japan.
Mina MatsuoLife Science Research Center, University of Toyama, Toyama, Japan.
Kimihiro KimuraDepartment of Behavioral Physiology, Graduate School of Innovative Life Science, University of Toyama, Toyama, Japan.
Takashi SaitoDepartment of Neurocognitive Science, Institute of Brain Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Takaomi C SaidoLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Saitama, Japan.
Keizo TakaoDepartment of Behavioral Physiology, Faculty of Medicine, University of Toyama, 2630 Sugitan, Toyama, 930-0194, Japan. takao@cts.u-toyama.ac.jp.

Funding

Japan Society for the Promotion of Science 22H04922
6 · The paper itself

Abstract

Women are at higher risk for Alzheimer's disease (AD) than men and hormonal changes during perimenopause are considered a risk factor. The relationship between ovarian hormones and AD has been explored using AD animal models, especially through ovariectomy (OVX) in established AD models. The link between early-stage AD and ovarian hormones, however, remains unclear, largely due to the lack of suitable animal models. Appropriate models for studying early-stage AD pathology, treatment, and prevention are critically needed. The App knock-in mouse model, which carries a single amyloid precursor protein (App) gene mutation, effectively reproduces early amyloid AD pathology. To elucidate the relationship between ovarian hormone deficiency and the behavioral phenotypes of a preclinical AD model, we applied a comprehensive behavioral test battery to this mouse model with bilateral OVX. The App mutation reduced anxiety-like behavior and impaired performance in the fear memory task. OVX restored the anxiety-like behavior of the App mutation mice to a level comparable to that in wild-type (WT) mice. Furthermore, OVX enhanced performance in a fear memory task in both genotypes and reduced amyloid-β staining in WT mice. Together, these findings suggest that OVX attenuates AD-related phenotypes in a preclinical AD model and in C57BL/6 J WT mice.

Indexed as

Alzheimer DiseaseOvariectomyAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsAnxietyBehavior, AnimalDisease Models, AnimalFearFemaleGene Knock-In TechniquesMemoryMiceMice, Inbred C57BLMice, TransgenicMutationAmyloid beta-PeptidesAmyloid beta-Protein Precursor

Identifiers

PMID41152341
PMCPMC12568933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.